Ablynx NV (ABLX.BR)
|Market Cap (Mil.):||€470.27|
|Shares Outstanding (Mil.):||53.99|
Announces that it has raised 41,720,822 through a private placement of new shares via an accelerated
BRIEF-Ablynx's anti-vWF nanobody, caplacizumab, achieves clinical proof-of-concept in phase II titan study
* Ablynx's anti-vwf nanobody, caplacizumab, achieves clinical proof-of-concept in phase ii titan study
BRUSSELS, May 14 - Belgian biotech group Ablynx said its cash reserves increased in the first quarter after an upfront payment from Merck & Co as part of a research deal for immune oncology.
* Anticipated that top-line phase II data from Titan study with Caplacizumab will be reported in June 2014
* Ablynx initiates phase I bioavailability study with subcutaneous formulation of its anti-il-6R nanobody partnered with Abbvie
BRUSSELS, Feb 27 - Ablynx NV : * Says FY revenue growth of 34 pct to 35.9 million euros * Says net loss for the period reduced by 32 pct to 19.5 million euros (2012: 28.5 million euros) * Says fourfold increase in cash-income from collaborations to 157.6 million euros (2012: 36.5 million euros)
BRUSSELS, Feb 27 - Belgian biopharmaceutical company Ablynx reported a 34 percent rise in revenue in 2013 and ended the year with a large cash pile, although cautioned that it would burn through more of it this year than last.
BRUSSELS - Belgian biotech company Ablynx has signed a deal with Merck & Co worth up to 1.7 billion euros ($2.3 billion) to develop ways of triggering the body to fight cancer by itself.
BRUSSELS, Feb 3 - Belgian biotech company Ablynx has signed a deal with Merck & Co worth up to 1.7 billion euros ($2.29 billion) to develop potential new treatments for cancer.
BRUSSELS, Feb 3 - Ablynx NV : * Announces worldwide cancer immunotherapy discovery collaboration and licensing agreement with Merck * Collaboration, licensing agreement is focused on the discovery and development of several predefined nanobody candidates * Co will receive an upfront payment of 20 mln euros; up to 10.7 mln euros in research funding during the initial three year * Is eligible to receive development, regulatory and commercial milestone payments on achieved sales thre
Earnings vs. Estimates
Analyst Research Reports
Ablynx NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.